Retatrutide vs Survodutide: Comparing Two Glucagon-Containing Agonists

Overview

Retatrutide and survodutide both add glucagon receptor activation to incretin-based treatment, but they come at it from opposite directions. Retatrutide adds GCGR to the GIP/GLP-1 dual agonist design, making a triple agonist. Survodutide (developed by Boehringer Ingelheim, also known as BI 456906) adds GCGR to GLP-1R activation, making a GLP-1/glucagon dual agonist without GIP. Comparing them shows what GIP receptor activation adds, since that is the one thing that differs.

Both programs now have Phase 3 obesity data. Retatrutide has two positive readouts: TRIUMPH-4 (-28.7% at 68 weeks in obesity + knee OA, December 2025) and TRIUMPH-1 (-28.3% at 80 weeks in obesity without diabetes, May 21, 2026). Survodutide’s Phase 3 SYNCHRONIZE-1 reported on April 28, 2026: -16.6% mean weight loss at 76 weeks in obesity without type 2 diabetes (efficacy estimand), with 85.1% of participants losing ≥5% versus 38.8% on placebo. Full results were presented at the American Diabetes Association 2026 Scientific Sessions in June 2026 and published in NEJM. SYNCHRONIZE-2 (obesity with type 2 diabetes) followed on October 1, 2026: up to -13.1% at 76 weeks versus -3.1% on placebo (efficacy estimand). The Phase 3 efficacy gap is now large: retatrutide roughly doubles survodutide’s average weight loss.

Important caveat: No head-to-head trial has compared these drugs. Cross-trial comparisons have real limits.

Why This Comparison Matters

This comparison is unusually useful in metabolic pharmacology:

• These are the only two late-stage drugs that include glucagon receptor activation, so we can see its effects in two different receptor combinations
• It isolates the value of GIP receptor activation: retatrutide has it, survodutide does not, and both share GLP-1 and glucagon receptor activity
• Both drugs are aimed at MASLD/MASH, where glucagon receptor activation benefits the liver directly, which makes the comparison especially relevant to liver disease
• The drugs come from different companies (Eli Lilly and Boehringer Ingelheim) with different strategies, showing how the same principle (glucagon receptor activation) can be applied in different clinical settings
• With Phase 3 obesity data for both drugs, the comparison now rests on Phase 3 results rather than Phase 2 estimates

Mechanism Comparison

Shared Pathways

Both molecules share two receptor targets:

• GLP-1 receptor: Providing appetite suppression, glycemic control, and gastric motility effects
• Glucagon receptor: Providing increased energy expenditure and hepatic fatty acid oxidation

Because both act on GCGR, both should raise energy use and cut liver fat, the hallmarks of glucagon-containing agonists. Glucagon receptor activation affects the liver in the same way with either molecule: it stimulates fat burning in the mitochondria, raises heat production and speeds fat clearance.

The Differentiating Factor: GIP Receptor

The key difference is whether the drug activates the GIP receptor (retatrutide) or not (survodutide):

GIPR activation may give retatrutide extra benefits for fat tissue function, insulin secretion and possibly body composition during weight loss. Survodutide’s simpler two-receptor design, on the other hand, may be easier to manufacture and more predictable pharmacologically.

TRIUMPH-4 Phase 3 Results

TRIUMPH-4, released in December 2025, gave the first Phase 3-level evidence of retatrutide’s efficacy. In 445 adults with obesity and knee osteoarthritis:

• Retatrutide 12 mg: -28.7% mean weight loss at 68 weeks
• Retatrutide 9 mg: -26.4% mean weight loss at 68 weeks
• 58.6% of participants at 12 mg lost at least 25% of their body weight (1.3% on placebo)
• 75% reduction in knee osteoarthritis pain scores

This is the largest weight loss ever achieved by any drug in a Phase 3 trial. It is well above the Phase 2 result (-24.2% at 48 weeks) and widened the apparent gap with survodutide’s Phase 2 weight loss.

TRIUMPH-4 also found a new safety signal: dysesthesia (abnormal sensations) in 20.9% of participants at 12 mg versus 0.7% on placebo.

Efficacy Comparison

Weight Loss

Both drugs now have Phase 3 obesity data, so the comparison no longer depends on Phase 2 numbers for either.

The Phase 3 gap is now clear: in the most comparable population (obesity without T2D), retatrutide produces about 12 percentage points more weight loss than survodutide. That is about 1.7 times survodutide’s average weight loss, and a much bigger gap than Phase 2 had suggested.

The most likely reason is the GIP receptor activation that retatrutide has and survodutide lacks. GIPR adds appetite suppression, fat tissue remodeling and extra insulin release, and all of these appear to translate into measurably more weight loss when added to a GLP-1/glucagon backbone. GLP-1/glucagon dual agonism also has a narrower blood sugar safety margin (without GIPR-driven insulin release), which may limit how far survodutide’s dose can be pushed.

Liver Fat

Both drugs cut liver fat substantially, thanks to their shared glucagon component:

• Survodutide: Cut liver fat significantly in Phase 2, with a particular focus on people with MASLD/MASH. Boehringer Ingelheim has made MASH a key indication, with trials using liver biopsy endpoints. Phase 2 showed clinically meaningful improvement in liver tissue in MASH patients.
• Retatrutide: Cut liver fat by ~82% in relative terms in Phase 2. GIPR-driven gains in insulin sensitivity and fat handling elsewhere in the body may boost the liver effect further. Eli Lilly’s SYNERGY trial is testing retatrutide for MASH.

Both drugs are being developed as possible MASLD/MASH treatments, and their effects on liver fat may be among the strongest of any drug class.

Glycemic Control

Retatrutide may control blood sugar better because GIPR activation adds more insulin release. With both GLP-1R and GIPR driving insulin, retatrutide produces stronger glucose-dependent insulin secretion, which better offsets GCGR’s glucose-raising effect. Survodutide has only GLP-1R-driven insulin release to offset GCGR-driven glucose output from the liver, which may leave a narrower margin for blood sugar safety.

In Phase 2 type 2 diabetes data, retatrutide lowered HbA1c by about -2.02% (and by -1.94 points at 12 mg in the Phase 3 TRANSCEND-T2D-1 trial). In SYNCHRONIZE-2, survodutide lowered HbA1c by up to 1.21 points from a baseline of 7.4% at 76 weeks (efficacy estimand).

Safety Considerations

Gastrointestinal Events

Both drugs cause GI side effects through GLP-1R. On the data available, adding GIPR in retatrutide does not seem to make GI effects much worse. Survodutide’s Phase 2 data also showed GI effects typical of GLP-1R drugs, with nausea, vomiting and diarrhea the most common.

Dysesthesia

TRIUMPH-4 found dysesthesia as a new safety signal for retatrutide (20.9% at 12 mg versus 0.7% placebo). It is not yet clear whether it comes from the glucagon component (which would in theory affect survodutide too) or from the specific three-receptor combination. Survodutide’s Phase 2 data did not report a similar signal, but the smaller Phase 2 trials may not have been able to detect it.

Glycemic Safety

For both drugs, the balance between GCGR raising blood sugar and GLP-1R lowering it is a critical safety issue. Retatrutide’s extra GIPR-driven insulin release may give it a wider margin, lowering the chance that GCGR activity causes high blood sugar. Survodutide relies entirely on GLP-1R to offset GCGR.

Hepatic Safety

Both drugs need long-term liver monitoring because they activate GCGR continuously. With a shared glucagon component, both carry similar theoretical liver safety questions, though their receptor potency ratios and tissue exposure may differ.

Development Strategy Differences

Boehringer Ingelheim (Survodutide)

Boehringer Ingelheim has put survodutide’s main emphasis on MASLD/MASH, running dedicated liver trials with tissue endpoints (liver biopsy before and after treatment). That focus reflects both how the drug works (GLP-1/glucagon dual agonism suits liver disease) and a decision to stand apart from the crowded obesity/diabetes field. Phase 3 trials for both obesity and MASH are underway as of May 2026.

Eli Lilly (Retatrutide)

Eli Lilly’s Phase 3 TRIUMPH program mainly targets obesity and type 2 diabetes, with 7 TRIUMPH trials plus the TRANSCEND (type 2 diabetes) and SYNERGY (MASH) studies. TRIUMPH-4, the first to report, focused on obesity with knee osteoarthritis. Liver fat reduction is an important secondary outcome, and the dedicated SYNERGY MASH trial shows Eli Lilly is also pursuing the liver indication.

Current Status and Availability

Retatrutide

Retatrutide has completed its pivotal Phase 3 program: TRIUMPH-4 (December 2025, -28.7%), TRANSCEND-T2D-1 (March 2026), TRIUMPH-1 (May 2026, -28.3%), and TRIUMPH-2 and TRIUMPH-3 (July 23, 2026: -20.8% in type 2 diabetes and -22.6% with cardiovascular disease). Nothing has been filed yet; Eli Lilly plans to file no later than Q1 2027, so the earliest possible FDA approval is late 2027 to mid-2028. The FDA ruled on October 2, 2026 that retatrutide is a drug, so the application must be a New Drug Application (NDA), which Lilly is contesting (the FDA ruling). Available only through clinical trials or Lilly’s narrow expanded access program.

Survodutide

Survodutide is in Phase 3 development for both obesity and MASH. SYNCHRONIZE-1 Phase 3 obesity results were reported on April 28, 2026: -16.6% mean weight loss at 76 weeks (efficacy estimand), with 85.1% of participants achieving ≥5% weight loss versus 38.8% on placebo (p<0.0001). Gastrointestinal events were mostly mild to moderate, with no new safety concerns. Full results were presented at the American Diabetes Association 2026 Scientific Sessions in June 2026 and published in NEJM. SYNCHRONIZE-2 (obesity + T2D) was presented at EASD 2026 and published in NEJM on October 1, 2026: up to -13.1% weight loss versus -3.1% on placebo and an HbA1c reduction of up to 1.21 points at 76 weeks (efficacy estimand). SYNCHRONIZE-CVOT (cardiovascular safety) is ongoing; on October 1, 2026 Zealand Pharma, Boehringer’s partner, said it expected results later in 2026. Survodutide also has FDA Breakthrough Therapy Designation for MASH, with dedicated Phase 3 liver-biopsy trials. As of October 2026, Boehringer Ingelheim had not announced filing dates. Available only through clinical trial enrollment.

What This Comparison Reveals About GIP

Setting retatrutide against survodutide gives indirect evidence of what GIP receptor activation adds to a GLP-1/glucagon design:

1. More weight loss: Retatrutide (triple) produces numerically more weight loss than survodutide (GLP-1/glucagon dual), which suggests GIPR adds weight benefit. Phase 3 TRIUMPH-4 data now support this
2. Blood sugar safety margin: GIPR-driven insulin release likely widens the window for adding GCGR activation safely
3. Fat tissue effects: GIPR’s effects on fat tissue may help improve body composition during weight loss
4. Added complexity: Each extra receptor target makes the drug more complex, which can complicate dose-finding and safety testing. The dysesthesia signal in TRIUMPH-4 is an example

Key Differences Summary

Treatments for MASH

Both retatrutide and survodutide may be able to treat metabolic dysfunction-associated steatohepatitis (MASH), which affects an estimated 6-8 million Americans and has few approved treatments.

Why Glucagon-Containing Agonists Are Promising for MASH

The glucagon receptor directly stimulates fat burning in the liver, which makes it well suited to reducing liver fat. GLP-1-only drugs lower liver fat mainly through weight loss and better insulin sensitivity. Glucagon receptor activation acts on the liver directly:

• Increased mitochondrial beta-oxidation of fatty acids in hepatocytes
• Enhanced hepatic energy expenditure
• Reduced de novo lipogenesis when combined with GLP-1R-mediated insulin sensitization

Both retatrutide and survodutide appear to cut liver fat more than GLP-1-only or GIP/GLP-1 dual agonists, which confirms the liver benefit of glucagon receptor activation.

Competitive Positioning

Boehringer Ingelheim’s sharp focus on MASH may give survodutide an edge in that indication, while Eli Lilly’s broader program (obesity, diabetes, MASH) spreads its resources across several regulatory filings.

Conclusion

Retatrutide and survodutide both bring glucagon receptor activation into incretin-based treatment, but from different angles. Retatrutide’s triple agonism covers the most receptors and has the strongest weight loss data, now confirmed at Phase 3 by TRIUMPH-4. Survodutide’s dual GLP-1/glucagon design is leaner and has been aimed squarely at MASLD/MASH.

Data from their Phase 3 programs will show the strengths of each approach more clearly. In particular, survodutide’s Phase 3 MASH and cardiovascular outcomes data will allow a firmer comparison once available. Both are important advances that could help different groups of patients.

Frequently Asked Questions

Which drug is more effective for weight loss, retatrutide or survodutide?

On the data available, retatrutide produces more weight loss. TRIUMPH-1 Phase 3 data showed -28.3% weight loss with retatrutide 12 mg at 80 weeks in adults with obesity without diabetes, while survodutide’s Phase 3 SYNCHRONIZE-1 showed -16.6% at 76 weeks in a similar population. The difference is likely driven by retatrutide’s extra GIP receptor activation. This is a cross-trial comparison, not a head-to-head result.

Why does retatrutide target three receptors while survodutide only targets two?

Different companies designed them with different strategies. Eli Lilly built retatrutide by adding glucagon receptor activity to its existing GIP/GLP-1 dual agonist expertise (from tirzepatide). Boehringer Ingelheim designed survodutide by combining GLP-1 with glucagon receptor activation, without GIP. Whether two or three receptors is best is still being researched.

Which drug is better for fatty liver disease (MASLD/MASH)?

Both drugs cut liver fat strongly because both act on the glucagon receptor. Boehringer Ingelheim has made MASH a main focus for survodutide, running dedicated trials with liver biopsy endpoints. Eli Lilly is testing retatrutide for MASH in the SYNERGY trial. Phase 2 data suggest retatrutide may cut liver fat more (~82% relative), but head-to-head and Phase 3 MASH data are needed for a firm answer.

Are these drugs available to patients now?

No. As of October 31, 2026, both retatrutide and survodutide are investigational and available only by enrolling in authorized clinical trials (and, for retatrutide, Lilly’s narrow expanded access program). Neither has been approved by the FDA, EMA or any other regulator. Neither can be prescribed or bought at a pharmacy.

What is the dysesthesia side effect, and does survodutide cause it too?

Dysesthesia means abnormal sensations (numbness, tingling, burning). It was reported in 20.9% of people on retatrutide 12 mg in TRIUMPH-4, a Phase 3 trial. Survodutide has not reported a similar signal, but its Phase 2 trials were smaller, which may limit detection of less common effects. Whether it is tied to the glucagon receptor (shared by both drugs) or to the three-receptor combination is not yet clear.

Which company has a stronger development program in this space?

Both companies have strong programs. Eli Lilly benefits from its established tirzepatide franchise (Mounjaro/Zepbound) and long experience with incretin drugs. Boehringer Ingelheim has partnered on survodutide and focused on MASH and liver disease. Eli Lilly’s TRIUMPH program is larger overall (7+ trials), while Boehringer Ingelheim’s narrow MASH focus may give survodutide a faster path to approval for that indication.

Do both drugs increase energy expenditure?

Yes. Both are expected to raise energy use through their shared glucagon component. Glucagon receptor activation stimulates heat production and fat burning in the liver, so the liver burns more calories. That sets both retatrutide and survodutide apart from GLP-1-only agonists (like semaglutide) and GIP/GLP-1 dual agonists (like tirzepatide), which mainly reduce calorie intake without much increase in energy use. Retatrutide’s GIP receptor activity may add to its metabolic effects, but the glucagon component is the main driver of higher energy use in both drugs.

When will we know which drug is better?

A definitive answer needs Phase 3 data from both programs and, ideally, a head-to-head trial. None has been done, and one may never be, since the drugs come from competing companies. Both programs now have Phase 3 obesity data (retatrutide: TRIUMPH-1 through TRIUMPH-4; survodutide: SYNCHRONIZE-1 and SYNCHRONIZE-2), which makes cross-trial comparisons more informative, though they still have methodological limits.